Ascletis Successfully Listed on the Main Board of HKEX
HONG KONG – (ACN Newswire) – Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been…
Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
Hangzhou and Shaoxing, China – (ACN Newswire) – Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug…
Ascletis-developed Ganovo Acquired Extraordinary Achievement
Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association HONG KONG – (ACN Newswire) – Ascletis announced on July 30,…